Envestnet Asset Management Inc. Buys 2,643 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

Envestnet Asset Management Inc. lifted its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Get Rating) by 12.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 24,485 shares of the company’s stock after buying an additional 2,643 shares during the period. Envestnet Asset Management Inc.’s holdings in CRISPR Therapeutics were worth $995,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Price T Rowe Associates Inc. MD raised its stake in CRISPR Therapeutics by 158.5% in the second quarter. Price T Rowe Associates Inc. MD now owns 3,014,551 shares of the company’s stock valued at $183,194,000 after buying an additional 1,848,437 shares during the period. State Street Corp boosted its holdings in shares of CRISPR Therapeutics by 228.8% in the 2nd quarter. State Street Corp now owns 1,569,860 shares of the company’s stock valued at $95,400,000 after purchasing an additional 1,092,384 shares in the last quarter. BlackRock Inc. boosted its holdings in shares of CRISPR Therapeutics by 79.2% during the 1st quarter. BlackRock Inc. now owns 2,278,774 shares of the company’s stock valued at $143,038,000 after acquiring an additional 1,007,246 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of CRISPR Therapeutics by 261.4% during the 1st quarter. Vanguard Group Inc. now owns 1,217,289 shares of the company’s stock valued at $76,410,000 after acquiring an additional 880,463 shares in the last quarter. Finally, Macquarie Group Ltd. raised its position in CRISPR Therapeutics by 830.3% during the 3rd quarter. Macquarie Group Ltd. now owns 837,435 shares of the company’s stock worth $54,791,000 after purchasing an additional 747,413 shares during the last quarter. 71.51% of the stock is owned by institutional investors and hedge funds.

CRISPR Therapeutics Trading Down 3.1 %

Shares of NASDAQ CRSP opened at $63.85 on Friday. The stock has a fifty day simple moving average of $52.18 and a two-hundred day simple moving average of $50.74. CRISPR Therapeutics AG has a 1-year low of $38.94 and a 1-year high of $86.95. The firm has a market cap of $5.04 billion, a price-to-earnings ratio of -9.50 and a beta of 1.71.

CRISPR Therapeutics (NASDAQ:CRSP – Get Rating) last announced its quarterly earnings data on Monday, May 8th. The company reported ($0.67) earnings per share for the quarter, beating the consensus estimate of ($1.64) by $0.97. The business had revenue of $100.00 million during the quarter, compared to analyst estimates of $24.33 million. CRISPR Therapeutics had a negative return on equity of 26.64% and a negative net margin of 516.43%. CRISPR Therapeutics’s revenue was up 10538.3% compared to the same quarter last year. During the same period in the prior year, the company earned ($2.32) earnings per share. Analysts forecast that CRISPR Therapeutics AG will post -6.59 EPS for the current year.

Insiders Place Their Bets

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 25,000 shares of the stock in a transaction on Tuesday, April 25th. The stock was sold at an average price of $50.67, for a total transaction of $1,266,750.00. Following the sale, the chief executive officer now owns 387,377 shares in the company, valued at $19,628,392.59. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders have sold a total of 75,000 shares of company stock worth $3,584,500 over the last 90 days. Corporate insiders own 4.10% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on CRSP shares. Morgan Stanley lifted their price objective on CRISPR Therapeutics from $37.00 to $39.00 and gave the stock an “underweight” rating in a research report on Monday, February 27th. Oppenheimer reduced their target price on CRISPR Therapeutics from $110.00 to $102.00 and set an “outperform” rating for the company in a research note on Thursday, February 23rd. Bryan, Garnier & Co initiated coverage on CRISPR Therapeutics in a research note on Friday, March 17th. They issued a “buy” rating and a $70.00 target price for the company. Citigroup raised their target price on CRISPR Therapeutics from $55.00 to $70.00 in a research note on Tuesday. Finally, Chardan Capital reduced their target price on CRISPR Therapeutics from $153.00 to $123.00 and set a “buy” rating for the company in a research note on Wednesday, February 22nd. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat.com, CRISPR Therapeutics presently has an average rating of “Hold” and a consensus price target of $74.89.

CRISPR Therapeutics Company Profile

(Get Rating)

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.